SAN DIEGO--Structural Bioinformatics (SBI) here and BioChem Therapeutics, a wholly owned subsidiary of Biochem Pharma, Laval, Quebec, have agreed to collaborate on drug discovery and design using SBI's proprietary computational technologies. SBI will apply its genomics-driven, protein-structure-based drug design algorithms to facilitate the design and identification of small molecules for two targets selected by BioChem. BioChem will contribute drug development expertise, fund the research, and make milestone and royalty payments.